Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany
Martin Olivieri, Songkai Yan, Ying Yang, Radovan Tomic et autres
INTRODUCTION: In Germany, three extended half-life factor IX (FIX) products are commonly used to treat people with haemophilia B (PwHB). However, there remains a critical need to differentiate treatments for PwHB. The aim of this study was to assess the effectiveness and …
de, us (code pays fourni par la source)
2 citations
Advances in Therapy